Since c-Met amplification leads to shorter survival in patients with gastric cancer and NSCLC [45,46], we assessed the tumor inhibitory capability of IRCR201 in a c-Met-amplified tumor model to provide clinical benefit in patients. This evidence concerns the gene MET and gastric cancer.